Applied DNA and Stratum Reservoir (Isotech) Sign Memorandum of Understanding to Leverage Isotopic Analysis for Enhanced DNA-Based Cotton Authenticity and Provenance
Applied DNA Sciences (NASDAQ: APDN) has signed a Memorandum of Understanding (MoU) with Stratum Reservoir's Isotech division to enhance cotton traceability using isotopic analysis (IA). This partnership aims to integrate IA as a confirmatory assay within Applied DNA's CertainT® platform, ensuring the authenticity of cotton fiber origins. This collaboration follows a presentation at an AAFA event detailing the successful identification of Egyptian cotton origins. Both companies are also working on a global database for cotton samples to support business development opportunities.
- Collaboration with Isotech to enhance cotton traceability using isotopic analysis.
- The integration of IA with the CertainT® platform strengthens supply chain assurance.
- Joint presentation of initial data at an AAFA event demonstrates advanced methodology.
- None.
The signing of the MoU follows the joint presentation of initial data by the companies at an
“Stable isotope analysis is a powerful tool that we have historically used in the oil and gas industry,” said
About
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a high-throughput turnkey solution for population-scale COVID-19 testing. safeCircle is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies that increase testing efficiencies and provide for rapid turn-around-times. The Company has also submitted a request for an EUA-authorization for its LineaTM
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
About
Isotech is a leading provider of laboratory services and equipment designed to deliver scientific insights for customers around the world, including specializing in high-precision carbon, hydrogen, oxygen, nitrogen and sulfur-isotope analysis for a variety of industries. Isotech is a member of the Stratum Reservoir group of companies, which operates rock and fluids analysis laboratories to enable the discovery and sustainable development of energy resources through applied geosciences.
For more information, visit www.stratumreservoir.com and follow us on LinkedIn.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, including Applied DNA's ability to successfully enter into commercial contracts for the implementation of its CertainT® platform, the unknown ability to identify and commercialize large numbers of cotton geographic biomarkers, the uncertainties inherent in research and development, and various other factors detailed from time to time in Applied DNA's
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005459/en/
For Applied DNA:
Investors:
Program Manager:
Web: www.adnas.com
Twitter: @APDN
For Isotech:
Media Inquiries:
Program Manager:
Source:
FAQ
What is the MoU between Applied DNA (APDN) and Isotech?
What are the benefits of the partnership between APDN and Isotech?
When was the MoU between Applied DNA Sciences and Isotech announced?
What is the CertainT® platform by Applied DNA?